Best Practices for the Nutritional Management of Infantile-Onset Lysosomal Acid Lipase Deficiency: A Case-Based Discussion
Authors:
- Fiona J. WhiteFWFiona J. White
- Javier de Las HerasJHJavier de Las Heras
- Celia Rodríguez-BorjabadCRCelia Rodríguez-Borjabad
- Simon A. JonesSJSimon A. Jones
- Alexander Y. KimAKAlexander Y. Kim
- Jenna MooreJMJenna Moore
- Florian AbelFAFlorian Abel
- Laura FrankLFLaura Frank
- Rosie JonesRJRosie Jones
- Suresh VijaySVSuresh Vijay
Open Access
Abstract
Infantile-onset lysosomal acid lipase deficiency (LAL-D) (Wolman disease, historically) is a rare inherited, rapidly progressive disorder caused by pathogenic variants in the LIPA gene, which encodes the enzyme LAL. LAL is essential for the metabolism of cholesteryl esters and triglycerides. LAL deficiency leads to the accumulation of cholesteryl esters and triglycerides within the lysosomes, macrophages, and parenchymal cells in most tissue types, including those in the liver, gastrointestinal tract, and lymph nodes but excluding the central nervous system. Infants with rapidly progressive LAL-D present with gastrointestinal disturbance, adrenomegaly with calcification, hepatosplenomegaly, growth failure due to malabsorption, and systemic inflammation. If untreated, rapidly progressive LAL-D typically leads to death within the first year of life. Treatment takes the two-pronged approach of sebelipase alfa, a human lysosomal acid lipase enzyme replacement therapy (ERT) that improves lipid metabolism, combined with nutritional management. Dietary substrate (lipid) reduction, known as substrate reduction therapy, is essential for optimal management in LAL-D. Following a nutritional plan and managing gastrointestinal disturbances together reduce systemic inflammation and improve growth, gut function, liver health, quality of life, and survival in patients with infantile-onset LAL-D. A multidisciplinary specialized team is necessary to manage the highly complex, multisystemic conditions in these patients. Nutritional management of LAL-D has evolved with increasing experience with the clinical management of ERT-treated infantile-onset LAL-D. A review of guidance for best practice nutritional management is needed. This narrative review aims to provide updated recommendations and guidance for the optimal nutritional management of infantile-onset LAL-D.Keywords
Funding Information
- Kimberly MacKenzie, PhD, of Peloton Advantage, LLC, an OPEN Health company
- Alexion, AstraZeneca Rare Disease
This publication has 36 references indexed in Scilit:
- Change to Mixed-Lipid Emulsion From Soybean Oil–Based Lipid Emulsion in Pediatric PatientsJAMA Network Open, 2023
- Impact of (intestinal) LAL deficiency on lipid metabolism and macrophage infiltrationMolecular Metabolism, 2023
- Recent insights into lysosomal acid lipase deficiencyTrends in Molecular Medicine, 2023
- High versus low medium chain triglyceride content of formula for promoting short-term growth of preterm infantsCochrane Database of Systematic Reviews, 2021
- Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2019
- Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic TargetTrends in Pharmacological Sciences, 2019
- Lysosomal acid lipase deficiency – An under-recognized cause of dyslipidaemia and liver dysfunctionAtherosclerosis, 2014
- Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanationEuropean Journal of Pediatrics, 2014
- Unfavorable outcome of hematopoietic stem cell transplantation in two siblings with Wolman disease due to graft failure and hepatic complicationsMolecular Genetics and Metabolism, 2013
- Cholesteryl ester storage disease: Review of the findings in 135 reported patients with an underdiagnosed diseaseJournal of Hepatology, 2013